Secondary acute myeloid leukemia after etoposide therapy for retinoblastoma.
Retinoblastoma is the most common eye tumor in children and is highly curable. Patients with hereditary retinoblastoma, have an increased risk of developing additional tumors, predominantly sarcomas. Most chemotherapy regimens used in retinoblastoma include etoposide, an epipodophyllotoxin associated with a risk of secondary myeloid leukemia. The use of etoposide in patients with a cancer predisposition syndrome such as retinoblastoma is potentially harmful, however, reports of secondary acute myeloid leukemia in patients treated with etoposide for retinoblastoma are rare. We report a case of a patient who developed secondary acute myeloid leukemia after etoposide treatment for retinoblastoma.
Weintraub
Michael
M
Department of Pediatric Hematology-Oncology, Hadassah University Hospital, Jerusalem, Israel. michalew@hadassah.org.il
Revel-Vilk
Shoshana
S
Charit
Mira
M
Aker
Memet
M
Pe'er
Jacob
J
Pèer
Jacob
J
D000208:Acute Disease; D000972:Antineoplastic Agents, Phytogenic / Q000009:adverse effects* / Q000627:therapeutic use; D005047:Etoposide / Q000009:adverse effects* / Q000627:therapeutic use; D005260:Female; D006801:Humans; D007223:Infant; D007951:Leukemia, Myeloid / Q000139:chemically induced* / Q000175:diagnosis*; D019572:Retinal Neoplasms / Q000188:drug therapy*; D012175:Retinoblastoma / Q000188:drug therapy*; D016896:Treatment Outcome